| Literature DB >> 32978121 |
Seth A Berkowitz1, Yuchiao Chang2,3, Bianca Porneala3, Sara J Cromer4, Deborah J Wexler5,4, Linda M Delahanty5,4.
Abstract
INTRODUCTION: We aimed to test the effectiveness of a lifestyle intervention (LI) for individuals with food insecurity and type 2 diabetes. RESEARCH DESIGN AND METHODS: Adults with type 2 diabetes, body mass index ≥25 kg/m2 (or ≥23 kg/m2 if Asian), hemoglobin A1c of 6.5%-11.5% (48-97 mmol/mol) and who were willing to lose 5%-7% bodyweight were enrolled in REAL HEALTH-Diabetes. This practice-based randomized clinical trial compared LI (delivered inperson or by telephone) with medical nutrition therapy (MNT) on weight loss at 6 and 12 months. Two or more affirmative responses on the six-item US Department of Agriculture Food Security Survey Module indicated food insecurity. In this prespecified subgroup analysis, we tested using linear mixed effects models whether the intervention effect varied by food security status.Entities:
Keywords: diabetes mellitus; type 2; weight reduction programs
Mesh:
Substances:
Year: 2020 PMID: 32978121 PMCID: PMC7520816 DOI: 10.1136/bmjdrc-2020-001514
Source DB: PubMed Journal: BMJ Open Diabetes Res Care ISSN: 2052-4897
Participant characteristics by food security status
| All | Food secure | Food insecure | P value* | |
| n | 208 | 180 | 28 | |
| Study arm, n (%) | 1.00 | |||
| Lifestyle intervention | 142 (68.3) | 123 (68.3) | 19 (67.9) | |
| Medical nutrition therapy | 66 (31.7) | 57 (31.7) | 9 (32.1) | |
| Age, mean (SD) | 61.7 (10.2) | 62.3 (9.9) | 58.0 (11.5) | 0.072 |
| Female, n (%) | 115 (55.3) | 93 (51.7) | 22 (78.6) | 0.008 |
| Race/ethnicity, n (%) | <0.0001 | |||
| Non-Hispanic white | 160 (76.9) | 148 (82.2) | 12 (42.9) | |
| Non-Hispanic black | 9 (4.3) | 9 (5.0) | 0 (0.0) | |
| Hispanic/Latino | 28 (13.5) | 14 (7.8) | 14 (50.0) | |
| Non-Hispanic Asian | 7 (3.4) | 5 (2.8) | 2 (7.1) | |
| Other | 4 (1.9) | 4 (2.2) | 0 (0.0) | |
| Education, n (%) | 0.0001 | |||
| Less than high school diploma | 17 (8.2) | 10 (5.6) | 7 (25.0) | |
| High school diploma or GED | 43 (20.7) | 39 (21.7) | 4 (14.3) | |
| 1–3 years of college | 60 (28.8) | 47 (26.1) | 13 (46.4) | |
| 4 or more years of college or graduate school | 88 (42.3) | 84 (46.7) | 4 (14.3) | |
| Annual income, n (%) | <0.0001 | |||
| <$30 000 | 48 (23.1) | 30 (16.7) | 18 (64.3) | |
| $30 000–$50 000 | 21 (10.1) | 19 (10.6) | 2 (7.1) | |
| $50 000–$100 000 | 68 (32.7) | 65 (36.1) | 3 (10.7) | |
| ≥$100 000 | 62 (29.8) | 60 (33.3) | 2 (7.1) | |
| Did not report | 9 (4.3) | 6 (3.3) | 3 (10.7) | |
| Insurance, n (%) | 0.001 | |||
| Commercial | 88 (42.3) | 80 (44.4) | 8 (28.6) | |
| Medicaid | 29 (13.9) | 25 (13.9) | 4 (14.3) | |
| Medicare | 59 (28.4) | 55 (30.6) | 4 (14.3) | |
| Medicare and Medicaid (‘dual eligible’) | 26 (12.5) | 16 (8.9) | 10 (35.7) | |
| Self-pay | 6 (2.9) | 4 (2.2) | 2 (7.1) | |
| Spanish language, n (%) | 17 (8.2) | 9 (5.0) | 8 (28.6) | 0.0004 |
| Baseline hemoglobin A1c | 7.7 (1.2) | 7.7 (1.2) | 8.0 (1.2) | 0.25 |
| mmol/mol, mean (SD) | 61.1 (12.8) | 60.6 (12.7) | 63.7 (13.2) | |
| Baseline body mass index, kg/m2, mean (SD) | 35.0 (5.4) | 35.0 (5.5) | 35.3 (4.7) | 0.75 |
| Baseline weight, kg, mean (SD) | 98.1 (18.9) | 98.9 (19.2) | 93.4 (16.1) | 0.11 |
| Baseline use of any glucose-lowering medication | 191 (91.8) | 163 (90.6) | 28 (100) | 0.14 |
| Baseline use of metformin | 166 (79.8) | 141 (78.3) | 25 (89.3) | 0.21 |
| Baseline use of insulin | 69 (33.2) | 53 (29.4) | 16 (57.1) | 0.005 |
| Baseline use of GLP-1 RA | 14 (6.7) | 13 (7.2) | 1 (3.6) | 0.70 |
| Baseline use of sulfonylurea | 65 (31.3) | 58 (32.2) | 7 (25.0) | 0.52 |
| Baseline use of thiazolidinedione | 2 (1.0) | 2 (1.1) | 0 (0.0) | 1.00 |
| Baseline use of DPP-4 | 9 (4.3) | 8 (4.4) | 1 (3.6) | 1.00 |
| Baseline use of SGLT2 | 6 (2.9) | 4 (2.2) | 2 (7.1) | 0.19 |
*P value from two-sample t-tests for continuous variables and Fisher’s exact tests for categorical variables.
DPP-4, dipeptidyl peptidase-4 inhibitor; GED, General Education Development certificate; GLP-1 RA, glucagon-like peptide 1 receptor agonist; NGSP, National Glycohemoglobin Standardization Program; SGLT2, sodium/glucose cotransporter 2 inhibitor.
Per cent change in weight and hemoglobin A1c from baseline at 6 and 12 months
| Change in weight | Change in hemoglobin A1c, NGSP % (mmol/mol) | ||||||||||||
| 6 months | 12 months | 6 months | 12 months | ||||||||||
| n | Mean | SD | n | Mean | SD | n | Mean | SD | n | Mean | SD | ||
| Food security* | |||||||||||||
| Secure | MNT | 57 | −1.1 | 3.7 | 55 | −2.1 | 4.1 | 56 | −0.2 (2.5) | 1.0 (11.3) | 54 | −0.4 (3.9) | 1.3 (13.7) |
| LI | 122 | −5.1 | 5.3 | 122 | −4.7 | 6.1 | 120 | −0.6 (6.0) | 1.0 (11.5) | 122 | −0.3 (3.8) | 1.1 (12.4) | |
| Insecure | MNT | 9 | −1.3 | 3.3 | 9 | −0.9 | 3.8 | 9 | −0.5 (5.8) | 1.7 (18.6) | 8 | −0.5 (5.9) | 1.2 (13.4) |
| LI | 19 | −5.1 | 5.8 | 18 | −4.5 | 6.0 | 19 | −0.3 (3.6) | 0.8 (9.3) | 18 | −0.1 (1.5) | 0.7 (8.1) | |
| Income† | |||||||||||||
| <$30 000 | MNT | 17 | −1.0 | 3.5 | 16 | −1.1 | 3.6 | 17 | −0.2 (2.6) | 1.3 (14.3) | 16 | −0.3 (3.4) | 1.0 (11.1) |
| LI | 31 | −3.3 | 4.9 | 30 | −3.2 | 6.6 | 31 | −0.4 (4.4) | 0.7 (7.9) | 30 | −0.3 (2.8) | 0.8 (9.0) | |
| $30 000–$50 000 | MNT | 3 | −1.8 | 1.4 | 3 | −1.6 | 1.3 | 3 | −0.1 (0.7) | 0.6 (6.4) | 3 | 0.0 (0.4) | 0.7 (7.4) |
| LI | 18 | −5.4 | 4.2 | 18 | −4.3 | 5.7 | 18 | −0.6 (6.5) | 1.0 (11.2) | 18 | 0.0 (0.1) | 1.2 (13.5) | |
| $50 000–$100 000 | MNT | 17 | −1.2 | 3.5 | 17 | −2.2 | 3.5 | 16 | 0.1 (1.2) | 1.0 (11.0) | 16 | −0.1 (1.4) | 1.1 (11.6) |
| LI | 50 | −5.4 | 5.8 | 51 | −5.0 | 5.7 | 48 | −0.6 (6.8) | 1.3 (13.7) | 51 | −0.6 (6.0) | 1.2 (12.8) | |
| ≥$100 000 | MNT | 26 | −0.9 | 4.3 | 25 | −1.9 | 4.6 | 26 | −0.4 (4.6) | 1.1 (12.3) | 25 | −0.5 (5.2) | 1.5 (16.1) |
| LI | 36 | −6.1 | 4.9 | 35 | −5.5 | 5.4 | 36 | −0.5 (5.3) | 1.0 (11.0) | 35 | −0.3 (2.8) | 1.1 (12.2) | |
*P value for food security by intervention interaction was 0.99 for weight change and 0.27 for HbA1c change in the model adjusted for age, gender, race/ethnicity, education, primary language, income, and health insurance.
†Participants (4.3%) who did not report income are excluded from these analyses; p value for income category by intervention interaction was 0.69 for weight change and 0.29 for HbA1c change in the model adjusted for age, gender, race/ethnicity, education, primary language, and health insurance.
HbA1c, hemoglobin A1c; LI, lifestyle intervention; MNT, medical nutrition therapy; NGSP, National Glycohemoglobin Standardization Program.
Figure 1Percentage weight loss at 6 and 12 months by intervention arm (LI, lifestyle intervention; MNT, medically nutrition therapy) among those who are food insecure (FI) and food secure (FS). P value for interaction term testing whether the intervention effect varies among subgroups was 0.87 in unadjusted models and 0.99 in models adjusted for age, gender, race/ethnicity, education, primary language, income, and health insurance.
Figure 2Percentage weight loss at 6 and 12 months by intervention arm (LI, lifestyle intervention; MNT, medical nutrition therapy) by category of annual income (k indicates thousands of dollars). P value for interaction term testing whether the intervention effect varies among subgroups was 0.72 in unadjusted models and 0.69 in models adjusted for age, gender, race/ethnicity, education, primary language, income, and health insurance.